^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    R289

    i
    Other names: R289, R835 prodrug, R906289 Monosodium, R289 Na
    Associations

    News

    Trials
    Company:
    Rigel
    Drug class:
    IRAK-4 inhibitor, IRAK-1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS) (clinicaltrials.gov)
    P1b, N=34, Recruiting, Rigel Pharmaceuticals | N=22 --> 34 | Trial completion date: May 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Chr del(5q)
    |
    R289
    over1year
    PHASE 1B CLINICAL STUDY OF IRAK 1/4 INHIBITION FOR LOW-RISK MYELODYSPLASTIC SYNDROMES REFRACTORY/RESISTANT TO PRIOR THERAPIES: A TRIAL IN PROGRESS (EHA 2023)
    R289 is a prodrug that is converted to the active drug R835 in the gastrointestinal (GI) tract. Phase I, Myelodysplastic syndrome, Kinase inhibitor, MDS
    Clinical • P1 data
    |
    TLR4 (Toll Like Receptor 4) • IL1R1 (Interleukin 1 receptor, type I) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    R289
    over1year
    Phase 1b clinical study of IRAK 1/4 inhibition for low-risk myelodysplastic syndromes refractory/resistant to prior therapies. (ASCO 2023)
    R289 is a prodrug that is converted to the active drug R835 in the gastrointestinal (GI) tract. The trial is currently recruiting at 8 US sites. Clinical trial information: NCT05308264.
    Clinical • P1 data
    |
    TLR4 (Toll Like Receptor 4) • IL1R1 (Interleukin 1 receptor, type I) • NLRP3 (NLR Family Pyrin Domain Containing 3) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
    |
    R289